Navigation Links
Catalent Provides Commercial Manufacturing of Lexicon Pharmaceuticals' Orphan Drug XERMELO™ Following FDA Approval
Date:5/9/2017

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently welcomed Lexicon Pharmaceuticals, Inc.’s announcement that its pioneering orphan drug, XERMELO™, has been approved by the U.S. Food and Drug Administration (FDA). Catalent has been working in partnership with Lexicon since 2007 to develop the drug formulation, and will be manufacturing XERMELO for commercial supply.

XERMELO (telotristat ethyl) 250 mg is a first-in-class orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

“We are pleased that the skill and expertise that our scientists have dedicated to this project for ten years has resulted in this pioneering treatment reaching the market,” commented Matthew Mollan, Catalent's General Manager at its Kansas City, Missouri site. “Catalent first partnered with Lexicon when the drug was in Phase I development, and continued to support its manufacture through to supplying launch products.”

"We are proud to have discovered this ground-breaking orphan drug, and our successful collaboration with Catalent means we are now able to make it available for the thousands of patients currently suffering from this condition,” added Lonnel Coats, Lexicon's president and chief executive officer.

Carcinoid syndrome is a rare condition that occurs in patients living with metastatic neuroendocrine tumors (mNETs) and is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives, as well as by facial flushing, abdominal pain, fatigue and, over time, heart valve damage.

Catalent undertook development and manufacture of the drug at its 450,000-square-foot Kansas City facility, where the company provides a range of fully integrated support services, from formulation development and analytical testing, to clinical and commercial scale manufacturing and packaging of various oral dose forms.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at http://www.prweb.com/releases/2017/05/prweb14316592.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Catalent to Launch Innovative Fish Oil Supplement Product at Vitafoods Europe
2. Challenges and Strategies to Automate Potency Assays to be Discussed by Catalent Expert at Upcoming CASSS Bioassays Symposium
3. Catalent Expands Kansas City Clinical Storage and Secondary Packaging Capabilities to Meet Growing Demand for Cold Chain Services
4. Catalent Wins Prestigious Clinical Supply Chain Excellence Award at BioPharma Asia Convention
5. Challenges and Innovation in Clinical Trial Supply to be Presented by Catalent Experts at Upcoming Conferences
6. Catalent to Host Workshop with Leading Biologics Experts on Advanced Protein Development and Delivery at Upcoming Drug Delivery Partnerships Conference
7. Innovative Strategies for the Development of Lipid-based Oral Medicines to be Presented by Catalent and Gattefossé at Forthcoming Workshop
8. Accelerated Biopharmaceutical Development through Strategic Analytical Partnerships to be Discussed by Catalent Expert at Upcoming WCBP Conference
9. Catalent to Develop Softgel Capsules for JOT’s Leading Orphan Disease Candidates
10. Catalent Biologics Collaborates with PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine Research and Development
11. Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative: Helps Shape Better Supply Chain to Pharmaceutical and Healthcare Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... Houston, TX (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center ... the gold standard in tooth replacement and act as a support for prosthetic teeth, such ... fuses with the existing bone and becomes a sturdy, lasting new root for the tooth. ...
(Date:6/26/2017)... ... ... LARKR™ , an innovative new smartphone app providing on-demand talk therapy, ... join its online treatment platform. , Launching in just a few days, LARKR ... of people in need nationwide, and to supplement their traditional practices. Joining this network ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro ... in the timeline and write in the lyrics to any song. ProLyric flies in the ... line of the text can be added modularly for optimal control. ProLyric makes editing any ...
(Date:6/25/2017)... ... ... and the focus is on prostate cancer. Second only to skin cancer, prostate cancer ... cause of cancer related death today; lung cancer remains in the number one spot. Currently ... his lifetime. Those at highest risk are men who have a family history ...
(Date:6/24/2017)... ... , ... Doorknobs are for convenience, deadbolts are for security. , There are ... having an alarm system installed. But unless there is a working deadbolt lock that ... TX Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic Balloon Pumps ... ... CS100i IABP ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX 0998-00-3023-XX;  0998-UC-3023-XX ... This field correction also applies to any System 98 or ...
(Date:6/14/2017)... 14, 2017  In 2016, Embodied Labs ... pitch competition and came away with $25,000 in seed-fund ... by Forbes as "entering the life of another" and ... teaching "empathy to medical professionals in an entirely new ... named a finalist for the Department of Education,s EdSimChallenge, ...
(Date:6/10/2017)... K. Burchfield, DPM, is recognized by Continental Who,s Who as a ... Alabama . Dr. Burchfield serves as ... over 20 years of experience, as well as expertise in the ... "The podiatry professional ... to welcome you to his practice," the company,s website states. "We ...
Breaking Medicine Technology: